Cytoreductive Surgery and Hyperthermic Chemotherapy for Intrathoracic Pseudomyxoma Peritonei

Ann Thorac Surg. 2020 Dec;110(6):e541-e543. doi: 10.1016/j.athoracsur.2020.04.114. Epub 2020 Jun 15.


Dissemination of pseudomyxoma peritonei into the thoracic cavity is rare and carries a poor prognosis. Optimal treatment has not been defined. In our institution, patients have received cytoreductive surgery with hyperthermic intrathoracic chemotherapy, which demonstrated a good prognosis. A 51-year-old woman was referred to our hospital with right intrathoracic dissemination of pseudomyxoma peritonei. We performed parietal and mediastinal pleurectomy and simple resection of all visible tumors on the diaphragm and visceral pleura, followed by hyperthermic intrathoracic chemotherapy with 20 mg mitomycin at 42°C to 43°C. The patient had no evidence of disease progression in the thoracic cavity 1 year after surgery.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Chemotherapy, Adjuvant
  • Cytoreduction Surgical Procedures*
  • Humans
  • Hyperthermia, Induced*
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage*
  • Pseudomyxoma Peritonei / diagnosis
  • Pseudomyxoma Peritonei / drug therapy*
  • Pseudomyxoma Peritonei / surgery*


  • Antineoplastic Agents
  • Mitomycin